Laura Schrader, MD
Family Medicine · Charlotte, NCNPI 1568637247
Payments from drug & device makers
Across 174 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$410
- AstraZeneca$326
- Pfizer$229
- Amgen$206
- Lilly USA, LLC$173
- Johnson & Johnson$171
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,719100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $410 |
| AstraZeneca | 21 | $326 |
| Pfizer | 14 | $229 |
| Amgen | 13 | $206 |
| Lilly USA, LLC | 11 | $173 |
| Johnson & Johnson | 10 | $171 |
| Exact Sciences | 6 | $115 |
| Daiichi Sankyo Inc. | 7 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $103 |
| AbbVie(2 entities) | 6 | $91 |
| Boehringer Ingelheim | 5 | $69 |
| Astellas Pharma US Inc | 4 | $67 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Eisai Inc. | 4 | $53 |
| Abbott | 2 | $51 |
| GSK | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Neos Therapeutics, LP | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $36 |
| Phathom Pharmaceuticals, Inc. | 4 | $35 |
| Cranial Technologies, Inc | 2 | $31 |
| Genentech USA, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $28 |
| Boston Scientific | 1 | $27 |
| Merck | 2 | $25 |
| Antares Pharma, Inc. | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Tris Pharma Inc | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $11 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$2,719 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $172,195 |
| EliquisApixaban | 137 | $166,360 |
| XareltoRivaroxaban | 95 | $112,721 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $72,246 |
| MounjaroTirzepatide | 41 | $61,540 |
| JardianceEmpagliflozin | 19 | $28,756 |
| JanuviaSitagliptin Phosphate | 17 | $27,794 |
| LinzessLinaclotide | 18 | $18,811 |
| MyrbetriqMirabegron | 15 | $18,211 |
| FarxigaDapagliflozin Propanediol | 16 | $15,711 |
| Bydureon BciseExenatide Microspheres | 12 | $10,185 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $9,191 |
| SynthroidLevothyroxine Sodium | 98 | $8,493 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,971 |
| Omeprazole | 409 | $6,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $410 | $172,195106 claims |
| PfizerEliquis | $229 | $166,360137 claims |
| Johnson & JohnsonXarelto | $171 | $112,72195 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $46 | $79,217102 claims |
| Lilly USA, LLCMounjaro | $173 | $61,54041 claims |
| MerckJanuvia, Janumet Xr | $25 | $36,98429 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $69 | $33,82030 claims |
| AbbVieLinzess, Synthroid | $91 | $27,304116 claims |
| Astellas Pharma US IncMyrbetriq | $67 | $18,21115 claims |
| AstraZenecaFarxiga | $326 | $15,71116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Charlotte
- George RaadCharlotte$7.7M
- Steven BauerCharlotte$2.7M
- Melissa JonesCharlotte$1.8M
- Laura LuptonCharlotte$811K
- Kevin SodenCharlotte$558K
- Joseph KonenCharlotte$322K
- Thomas BarringerCharlotte$305K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Jewell CarrCharlotte$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.